On July 1, former Microsoft CEO and President Steve Ballmer surpassed Microsoft co-founder Bill Gates for the first time on the Bloomberg list of the world's richest people to become the sixth richest person in the world. According to the data, as of the same day, Ballmer's net worth reached $157.2 billion, while Gates's wealth was $156.7 billion, falling to seventh place. The latest figures, as of July 6, show that Ballmer's wealth has grown further to $161 billion, and Gates' wealth is $159 billion. This is the first time Ballmer's net worth has surpassed Gates', and it is also the rare time in history that an employee's net worth has surpassed that of a company founder. Unlike Musk, Jeff Bezos and others, Ballmer's wealth was not accumulated through entrepreneurial success as a business founder, but simply because he chose to hold Microsoft "indefinitely." As Fortune previously reported, Ballmer is the only individual with a net worth of more than $100 billion as an employee rather than a founder.

From the perspective of the two major markets of the United States and China, the autonomous driving industry has fallen into a low tide in recent years. For example, last year, Cruise Origin, one of the twin stars of Silicon Valley autonomous driving companies and once valued at more than $30 billion, failed completely, its Robotaxi (driverless taxi) operation qualification was revoked, and autonomous driving models have been discontinued. However, as a new track with the deep integration of digital economy and real economy, automatic driving is a must answer: on the one hand, automatic driving will accelerate the process of technology commercialization and industrialization, and become an important part of the game of major powers; On the other hand, autonomous driving will also promote industrial transformation and upgrading by improving the mass travel service experience, seeking new engines for urban development, and injecting new vitality into the urban economy.

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.

July 9 (Reuters) - The National Highway Traffic Safety Administration (NHTSA) has opened a recall query into 94,275 Stellantis-owned (STLAM.MI), opens new tab Jeep SUVs over a loss of motive power, the U.S. auto safety regulator said on Tuesday. The investigation targets Jeep's Wrangler 4xe hybrid SUVs manufactured between 2021 through 2024. Chrysler had previously recalled, opens new tab the same model in 2022 to address concerns related to an engine shutdown. A recall query is an investigation opened by safety regulators when a remedy to solve an issue appears inadequate. The complaints noted in the new report include both failures in vehicles that received the recall remedy and those not covered by the prior recall, the NHTSA said.